Accessibility

What we do

All interactive controls are reachable by keyboard with a visible focus indicator. Color is never the only carrier of meaning — dose tiers are labeled in text as well as color-coded, and price comparisons are marked in text rather than by color alone.

Motion respects the prefers-reduced-motion setting: the price ticker stops and transitions are suppressed.

Known gaps

Wide price tables scroll horizontally on narrow screens. We consider this preferable to truncating data, but if it creates a barrier for you, tell us and we will publish an alternative format.

Report a barrier

Email accessibility@glp1tirzepatiderx.com with the page and what failed. We treat accessibility reports as corrections and handle them on the same timeline.

Accessibility: how this site is actually built

Every price table, ranking and comparison on this site is generated from a structured dataset rather than written by hand. That has one consequence worth stating plainly: rankings are computed, not chosen. We cannot quietly move a program up a table, because there is no table to edit — there is a dataset and a sort order, both published. The dataset is downloadable, and so is the formula for the disclosure score.

We currently track 44 routes to tirzepatide or semaglutide, priced at all six dose tiers, with entry pricing for compounded preparations starting at $133 per month. Every record carries the date it was last verified, because a price without a date is not a fact, it is a memory.

Accessibility: what we will not do

We will not publish a price we cannot interpret. A figure advertised without the dose it applies to or the period it covers is left blank rather than estimated, and the blank is deliberate. We will not invent review counts, ratings or testimonials. We will not describe a compounded preparation as equivalent to an FDA-approved product, because FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before marketing. And we will not accept payment for placement, for position, or for the removal of a criticism.

Accessibility: the disclosure score in full

The score measures what a program publishes before you pay — not the quality of its care, which we have no way to measure and will not pretend to. Its seven inputs and weights:

1. Price published at all six dose tiers — 25 points.
2. Price does not rise as the dose escalates — 20 points.
3. Dispensing pharmacy or prescriber identified by name — 15 points.
4. No separate recurring membership fee — 10 points.
5. Prepaid term and its rate published — 10 points.
6. State availability published — 10 points.
7. Delivery formats published — 10 points.

All seven are derivable from the published dataset, which means anyone can recompute the number and get the same answer. If you think the weighting is wrong, take the data and weight it differently; that is why it is published.

Accessibility: how we handle conflicting sources

Where two sources give different prices for the same program, we show both, name each source and its date, and state that neither has been independently verified. Choosing one silently would produce a cleaner table and a less honest one. Those conflicts appear as callouts on the affected program pages.

Accessibility: commercial relationships

Some outbound links are commercial and may earn a commission. Commissions do not influence rankings, scores or published prices. Table order is computed from the published dataset rather than assigned, so the ranking can be reproduced from the files on the data page. Where we have no outbound link for a program, the page says so and suggests searching for it directly rather than following an advertisement. See the advertising disclosure for the full statement.

Accessibility: corrections

Substantive errors — a wrong price, a misstated dose, an incorrect trial result, a ranking moved by bad data — are logged publicly with the date they were fixed. A site publishing prices in a fast-moving market that never records a correction is not being careful; it is not checking. Report anything you believe is wrong through contact with the page URL and, if you have one, a source.

Accessibility: what this site is not

It is not medical advice, it is not a pharmacy, and it does not sell medication. Tirzepatide is a prescription medicine, and only a licensed clinician who has reviewed your history can decide whether it is appropriate for you. Compounded preparations are not FDA-approved. If a program guarantees approval before a clinician has seen your record, that is the clearest warning sign available in this market, and no price justifies it.

Accessibility: why any of this is worth stating

Health-adjacent comparison sites are structurally conflicted. They are funded by commissions from the companies they rank, which creates an incentive to rank the highest-paying option first and to describe the arrangement vaguely. The defences against that are boring and checkable: publish the dataset, publish the formula, compute the ranking rather than choosing it, disclose the commercial relationships in the same typeface as everything else, and log corrections publicly with dates.

None of that proves good faith. It does make bad faith detectable, which is the most any publisher can honestly offer. If our ranking and our published dataset ever disagree, that is a bug or a lie, and either way you can find it without our help.

Accessibility: how to check us

Download providers.json and sort it yourself by twelve-month cost. The order should match our tables. Recompute the disclosure score from the criteria and weights on the data page; the numbers should match the badges. Follow a trial citation to its registration record and confirm the endpoint we quoted was the primary one. Any mismatch is a reportable error and goes in the corrections log with the date it was fixed.

Accessibility: the limits of what a website can do

We can tell you what a program publishes and what it costs at each dose. We cannot tell you whether its clinicians are good, whether its shipments arrive on time, or whether tirzepatide is appropriate for you. The first two we do not measure and will not guess at; the third belongs to a licensed clinician with your medical history in front of them. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing, and no amount of comparison shopping changes that distinction.

Accessibility: the numbers behind the site

We track 44 routes to tirzepatide or semaglutide, priced at all six dose tiers, with compounded entry pricing from $133 to $399 a month and a cheapest twelve-month total of about $2,388. Every figure carries a verification date. Anything older than a month should be re-checked before you act on it, including by us.